Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

News Conference News VIVA 2025

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

November 07, 2025

What’s Going to Be Hot at AHA 2025?

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

Plant-Derived Compound Shows Early Promise for Small AAAs

News Conference News CX Symposium 2025

Plant-Derived Compound Shows Early Promise for Small AAAs

April 25, 2025

It’s Been 1 Year Since Medicare’s NCD for Carotid Stenting: What Now?

News Conference News VIVA 2024

It’s Been 1 Year Since Medicare’s NCD for Carotid Stenting: What Now?

November 14, 2024

Bioprosthetic Valve Dysfunction Tied to Worse Outcomes After AVR

News Conference News NY Valves 2024

Bioprosthetic Valve Dysfunction Tied to Worse Outcomes After AVR

June 14, 2024

New Carotid Stent Systems Associated With Low Stroke Risk

News Conference News VIVA 2023

New Carotid Stent Systems Associated With Low Stroke Risk

November 09, 2023

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

News Conference News CRT 2023

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

Yael L. Maxwell

March 03, 2023

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

Higher Subclinical Atherosclerosis in Black Americans Remains Unexplained

News Daily News

Higher Subclinical Atherosclerosis in Black Americans Remains Unexplained

Yael L. Maxwell

July 15, 2022

Embolic Protection Snags Debris in Nearly All Lower-Risk TAVI Patients

News Daily News

Embolic Protection Snags Debris in Nearly All Lower-Risk TAVI Patients

March 16, 2022

William R. Hiatt, Giant of Vascular Medicine, Dies at 70

News Daily News

William R. Hiatt, Giant of Vascular Medicine, Dies at 70

December 11, 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

News Conference News AHA 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

November 14, 2020

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

News Daily News

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

March 09, 2020

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

November 08, 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

March 06, 2019

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

March 01, 2019

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

November 13, 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

September 24, 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

September 22, 2018

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

News Conference News SCAI 2018

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

April 28, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.